Millennium Oncology Research Clinic
Welcome,         Profile    Billing    Logout  
 12 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Berenson, James R
NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Jun 2023 - Dec 2023: Completion of enrolment of trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
NCT03733691: Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Terminated
2
19
US
Ixazomib, Ninlaro, Lenalidomide, Revlimid
Oncotherapeutics, Takeda
Newly Diagnosed Multiple Myeloma
10/23
10/23
iinnovate-1, NCT03215030: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1/2
336
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda
Multiple Myeloma
02/24
09/24
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1/2
58
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
03/25
03/25
ORIC-533-01, NCT05227144: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Recruiting
1b
56
Canada, US
ORIC-533
ORIC Pharmaceuticals
Relapsed or Refractory Multiple Myeloma
06/24
06/24
NCT04519476: Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Recruiting
1
22
US
Selinexor, KPT-330, Lenalidomide, Revlimid, Methylprednisolone, Medrol
Oncotherapeutics, Karyopharm Therapeutics Inc
Refractory Multiple Myeloma
12/23
12/23
I-RUX-15-04, NCT03110822: A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Checkmark Data from I-RUX study for R/R multiple myeloma
Dec 2022 - Dec 2022: Data from I-RUX study for R/R multiple myeloma
Recruiting
1
134
US
Ruxolitinib Oral Tablet [Jakafi], Ruxolitinib, Jakavi, Lenalidomide, Revlimid, Methylprednisolone, Depo-Medrol, Solu-Medrol, Methyl Prednisolonate
Oncotherapeutics, Incyte Corporation
Multiple Myeloma
09/24
02/27
Levy, Isaac
NCT05161195 / 2021-005184-42: Roll-over Study to Allow Continued Access to Ribociclib

Recruiting
4
137
Europe, Japan, US, RoW
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Breast Cancer
02/30
03/30
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Calendar Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Calendar Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Data readout from DREAMM-8 trial in combination with pomalidomide and dexamethasone for 2L+ multiple myeloma
Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submissions in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Jun 2023 - Dec 2023: Completion of enrolment of trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32

Download Options